Finance

Lists
C17:FRA
Corvus Pharmaceuticals Inc
€8.70
-1.92%
(-0.17) 1D
Oct 9, 8:05:36 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for C17...
Open
€8.70
High
€8.70
Low
€8.70
Mkt. cap
859.72M
Avg. vol.
1.00
Volume
0.00
52-wk high
€21.70
52-wk low
€5.49
No. of employees
37
Open
€8.70
High
€8.70
Low
€8.70
Mkt. cap
859.72M
Avg. vol.
1.00
Volume
0.00
52-wk high
€21.70
52-wk low
€5.49
No. of employees
37
News stories
From web sources and news partners
About Corvus Pharmaceuticals Inc
CEO-
Employees37
Founded2014
HeadquartersBurlingame, California, United States
SectorBiotechnology
Websitecorvuspharma.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
8.45M
9.94M
11.18M
15.96M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.12M
2.28M
3.70M
3.33M
Operating expense
10.57M
12.22M
14.88M
19.30M
Total operating expenses
10.57M
12.22M
14.88M
19.30M
Operating income
-10.57M
-12.22M
-14.88M
-19.30M
Other non operating income
-
-
-
-
EBT including unusual items
-10.16M
-12.32M
-13.69M
-17.96M
EBT excluding unusual items
-10.16M
-12.32M
-13.69M
-17.96M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-10.16M
-12.32M
-13.69M
-17.96M
Net profit margin
-
-
-
-
Earnings per share
-0.12
-0.15
-0.15
-0.19
Interest and investment income
738.00K
603.00K
1.78M
2.05M
Interest expense
-
-
-
-
Net interest expenses
738.00K
603.00K
1.78M
2.05M
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.54M
-12.19M
-14.85M
-19.26M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps